Antibody-Drug Conjugate (ADC) Sequencing

Antibody-Drug Conjugate (ADC) Sequencing

Service Details


Antibody-drug conjugates (ADCs) are a class of drugs characterized by antibody scaffolds covalently modified with variable numbers of small molecule payloads. These drugs are mixed entities that combine biological and small molecule features. It combines the high targeting of monoclonal antibodies and the high efficiency of small molecule drugs in removing cancer cells, and can synergistically play the respective advantages of antibody drugs and chemical drugs. Antibodies are used to specifically target small molecules to target cell types. However, there are many unpredictable problems in the process of antibody drug conjugation, such as some of the antibodies and small molecules may not be successfully conjugated; there are multiple binding sites in the antibody; different Drug antibody ratio (DAR) may lead to change of hydrophobicity of the final ADC, etc. The existence of these problems may have a relatively large impact on the efficacy and safety of ADCs. At the same time, because the production process of ADCs is more complicated, the quality of ADCs needs to be strictly monitored. Therefore, the sequencing analysis of antibody-drug conjugates is of great significance.

Fig. 1. Schematic representation of ADC, showing the main components of an ADC and its cell cytotoxicity mechanism.Fig. 1. Schematic representation of ADC, showing the main components of an ADC and its cell cytotoxicity mechanism. (Nejadmoghaddam M R, et al., 2019)

Our Services

Creative Proteomics has developed the advanced mass spectrometry sequencing platform for ADC, with a high-resolution mass spectrometry analysis instruments. Combined with a professional bioinformatics analysis team, we can quickly and accurately provide you with professional and systematic ADC sequencing services. Our experienced scientists use the antibody sequencing platform developed by the company, using DASS (Database Assisted Shotgun Sequencing) technology, combined with the advantages of existing technology to analyze antibodies. It is an antibody sequencing platform based on mass spectrometry technology that this technology is also applicable to other subtypes and different forms of antibodies, such as: IgM, fluorescent conjugated antibodies, immobilized antibodies, antibodies of different species, etc.

At Creative Proteomics, the antibody-drug conjugate (ADC) sequencing service can provide professional monoclonal antibody sequencing services according to customer requirements, ensuring 100% accurate sequencing for all species, isotype antibodies or allotype antibodies.


  • Identification of Antibody Conjugates
    The traditional coupling method covalently connects cytotoxic drugs to lysine residues on antibodies or cysteine residues generated by the reduction of interchain disulfide bonds, and the obtained ADCs have a drug-to-antibody ratio , DAR) and coupling sites are highly variable, leading to greater heterogeneity. The conjugated antibody sequencing service can effectively identify the types of antibody conjugated drugs.
  • Detection of OCFS-Conjugated Antibody Production
    Deletion of the OCFS cell wall can add non-native factors to the system to manipulate transcription, translation and folding for precise regulation of protein expression processes. Conjugated antibody sequencing services can detect changes in the production of conjugated antibodies.

Creative Proteomics has accumulated extensive experience in the discovery and sequencing of therapeutic antibodies and proteins. We provide professional antibody-drug conjugate (ADC) sequencing services for global customers. Our team has successfully sequenced thousands of antibodies to help researchers decode their antibodies in a fraction of the time. Therefore, please contact us if you are interested in our antibody sequencing services.


  1. Ponziani S, Vittorio G D, Pitari G, et al. (2020) Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Int J Mol Sci. 21(15):5510.
  2. Nejadmoghaddam M R, Arash M T, Ghahremanzadeh R, et al. (2019) Antibody-Drug Conjugates: Possibilities and Challenges. Avicenna J Med Biotechnol. 1(1):3-23.

For research use only, not intended for any clinical use.

Online Inquiry